High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial

Lene Weber Vestermark, Helle A Jensen, Per Pfeiffer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Consensus is that patients with locally advanced rectal cancer (LARC) should receive long-term chemoradiotherapy (CRT) before surgery. With the intent to offer the patients intensified concomitant chemotherapy (CT) to improve outcome and to assess tolerability and toxicity of oxaliplatin (Ox) a phase I trial of high dose pelvic radiotherapy (RT), fixed dose of oral UFT/l-leucovorin and increasing doses of weekly Ox were performed.
OriginalsprogEngelsk
TidsskriftActa Oncologica
Vol/bind51
Udgave nummer3
Sider (fra-til)311-7
Antal sider7
ISSN0284-186X
DOI
StatusUdgivet - 2012

Fingeraftryk

Dyk ned i forskningsemnerne om 'High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater